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Background: The Notch signaling pathway is crucial in T-cell development, Notch1 mutations are frequently
present in T-cell acute lymphoblastic leukemia (T-ALL). To investigate the feature of Notch1 mutation and its
corresponding expression level in Chinese patients with T-ALL, detection of mutation and the expression level of
Notch1 gene was preformed using RT-PCR, sequencing and real-time PCR respectively.
Results: Two Notch1 point mutations (V1578E and L1593P) located on HD-N domain were identified in three cases
out of 13 T-ALL patients. The mutation on 4733 position (V1578E) found in two cases was a novel mutation. The
overexpression of Notch1 was detected in all samples with T-ALL, moreover, significantly higher expression of
Notch1 was detected in the T-ALL with Notch1 mutation group compared with T-ALL with WT Notch1 group (p =
0.0192).
Conclusions: Higher expression of Notch1 was associated with Notch1 mutation, more novel mutation of this gene
might be identified in different populations and its contribution to the molecular pathogenesis of T-ALL is needed
further research.
Background
T-cell acute lymphoblastic leukemia (T-ALL) which
occurs mainly via the proliferation of malignant T cell
clones, accounts for 15% of newly diagnosed ALL cases
in children and 20-25% of ALL cases in adults [1]. Over-
all, these are aggressive malignancies that do not
respond well to chemotherapy and have a poorer prog-
nosis than their B-cell counterparts [2]. Complex
acquired genetic aberrations include chromosomal
translocations (frequently involving TCR), as well as
gene rearrangements and mutations resulting in abnor-
mal expression of oncogenes like Notch1 may be asso-
ciated with the advance and resistance to treatment of
this disease [3].
Notch1 was discovered in 1991 through analysis of
rare T-cell lymphoblastic leukemia/lymphoma with
balanced (7;9) translocation [4]. Acquired Notch1 muta-
tions are present in about 50% of T-ALL [5,6]. More
than hundred different mutations frequently involved in
heterodimerization domain (HD), transactivation
domain (TAD) and praline, glutamic acid, serine, threo-
nine-rich (PEST) domains of Notch1w e r er e p o r t e di n
patients with T-ALL from a lot of researcher groups in
different countries [5-10]. Little is known the incidence
and feature of Notch1 mutations in Chinese T-ALL
patients [10], in this study, we detected the Notch1
mutations in 13 Chinese patients with T-ALL and ana-
lyzed the corresponding expression level of Notch1 gene.
Materials and methods
Samples
Thirteen newly diagnosed and untreated cases of T-
ALL, 11 males and 2 females (6-55 years old; median
age: 23.5 years) were included in this study, along with
20 healthy individuals as controls. The samples were
collected with informed consent. All procedures were
conducted in accordance with the guidelines of the
medical ethics committees of the Health Bureau of
Guangdong Province, China. The peripheral blood
mononuclear cells (PBMCs), RNA extraction using Tri-
zol reagent (Trizol
®, Invitrogen, Carlsbad, CA, USA)
and cDNA synthesis using random hexamer primers
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® III, Invitrogen,
Carlsbad, CA, USA) were performed according to the
manufacturer’s instructions.
RT-PCR and sequencing
To amplify different domain and exon of Notch1
according the structure of the Notch1 gene, 4-pair pri-
mers were purchased, which covered different exons,
where the mutations happen frequently (Table 1) [5,6].
RT-PCR was performed as our previous study, positive
control (Jurkat cell line) and negative control (non-tem-
plate) were included in each reaction [11,12]. The PCR
products were directly sequenced using a BigDye Termi-
nator v3.1 Cycle Sequencing kit (Perkin Elmer, ABI) and
the ABI PRISM 3100-Avant genetic analyzer. The
sequences from different samples of T-ALL were ana-
lyzed with the BLAST software (http://blast.ncbi.nlm.
nih.gov/Blast.cgi) to identify the mutations of Notch1
gene.
Real-time quantitative RT-PCR (qRT-PCR)
Expression levels of Notch1 and the reference gene b2M
were determined by SYBR Green I real-time PCR. PCR
was performed as our previous description [12,13]. The
2
(-ΔΔT) method was used to present the data of the
genes of interest relative to an internal control gene
[12-14]. The sequences of primers used in qRT-PCR
were listed in Table 1.
Statistical analysis
Univariate analyses were done using the Mann-Whitney
test to compare manes of Notch1 expression level
between T-ALL with Notch1 mutations or with wild-
type (WT) Notch1 status. P < 0.05 was considered as
statistically significant.
Results
Notch1 mutation and polymorphirsm in T-ALL
Notch1 expression was detected in all of 13 cases with
T-ALL by RT-PCR (Figure 1). The search for Notch1
mutation was performed in exon 26, 27 and 28 (HD),
TAD and PEST domain. The PCR products were direct
sequenced and revealed two mutations at nucleotide
position 4733 and 4778 respectively. The mutation on
4733 position was identified in two different cases, the
nucleotide sequence was changed from GTG to GAG
(codon 1578), thereby leading to an amino acid
exchange (Valine to Glutamic), this was a novel muta-
tion. While the mutation on 4778 position was identi-
fied in one case, the nucleotide sequence was changed
from CTG to CCG (codon 1593), leading to an amino
acid exchange from Leucine to Proline. All of mutations
presented were heterozygous genetic alteration. And the
mutations were located on HD N-terminus (Figure 2).
Sequence analysis of Notch1 segments revealed further a
nucleotide exchange in all samples analyzed at position
5094, where we found a cytosine instead of a thymine,
the alteration affected the third position of the codon
1698 and did not alter the amino acid sequence (data
not shown).
Expression level of Notch1 in T-ALL
In order to compare the expression level of Notch1g e n e
in different T-ALL samples with Notch1m u t a t i o n so r
with wild-type (WT) Notch1 status, the expression level
of Notch1 gene was analyzed by real-time PCR, in com-
parison with healthy controls (0.37 ± 0.33), significantly
higher expression of Notch1 was found in both T-ALL
with WT Notch1 (6.34 ± 7.03) (p = 0.0006) or with
Notch1 mutations (Mut Notch1) (20.47 ± 10.81) (p <
0.0001) (Figure 3). Moreover, significantly higher
Table 1 List of the primers used in RT-PCR and real-time PCR for Notch1 gene amplification
Primer
5,6 Sequence Domain PCR Function
notch26 + 27-F 5’-ACGACCAGTACTGCAAGGACC - 3’ HD/exon 26 + 27 RT-PCR Sense
notch26 + 27-R 5’- AAGAACAGAAGCACAAAGGCG - 3’ Antisense
notch28-F 5’- TCGCTGGGCAGCCTCAACATCC - 3’ HD/exon28 RT-PCR Sense
notch28-R 5’- ACTCATTCTGGTTGTCGTCC - 3’ Antisense
Notch TAD-F 5’- GCCCTCCCCGTTCCAGCAGTCT - 3’ TAD RT-PCR Sense
Notch TAD-R 5’- GCCTGGCTCGGCTCTCCACTCA - 3’ Antisense
Notch PEST-F 5’- CAGATGCAGCAGCAGAACCTG - 3’ PEST/exon34 RT-PCR Sense
Notch PEST-R 5’- AAAGGAAGCCGGGGTCTCGT - 3’ Antisense
Notch1-f 5’-GCGACAACGCCTACCTCT-3’ real-time PCR Sense
Notch1-r 5’-CTGCTGGCACAGTCATCC-3’ Antisense
b2M-f 5’-TACACTGAATTCACCCCCAC-3’ real-time PCR Sense
b2M-r 5’-CATCCAATCCAAATGCGGCA-3’ Antisense
Note: HD heterodimerization domain; TAD transactivation domain; PEST PEST domain.
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Page 2 of 5Figure 1 Results of RT-PCR amplification for Notch1 gene using different primer pairs which located in different domains. 1: 100 bp
DNA ladder, 2-3: Amplicon of Exon 26 and 27 (652 bp), 4-5: Amplicon of Exon 28 (316 bp), 6-7: Amplicon of TAD domain (666 bp), 8-9:
Ampilcon of PEST domain (530 bp).
Figure 2 Notch1 mutations in 3 cases with T-ALL (Mut sample) compared with a normal sequence of Notch1( W Ts a m p l e ) .
Heterozygous mutations were identified in position 4733 (codon 1578) and 4778 (codon 1593) in Notch1 gene.
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Mut Notch1 group compared with WT Notch1 group (p
= 0.0192) (Figure 3). Interesting, the expression level of
Notch1 in two cases with WT Notch1 T-ALL (24.28 and
9.06 respectively), which were not identified any muta-
tion in the present study, was as high as the samples
with Notch1 mutation.
Discussion
Notch1 signaling is crucial for T-cell differentiation and
proliferation, mutational activation of Notch1i sa n
important factor in T-ALL pathogenesis [5,7]. Translo-
cation and mutations of Notch1 may alter its function
resulting in overexpression and independent activation
[15]. In this study, Notch1 mutations were identified in
3 Chinese patients with T-ALL, the incidence of Notch1
mutation was only 23.08% (3/13), it seemed relatively
low in comparison with previous studies from different
European and American countries [5,6,16]. There are
rare studies described the incidence of Notch 1 mutation
in Chinese cases, one report by Zhu et al showed that
Notch1m u t a t i o nw a sf o u n di n2 9p a t i e n to u to f7 7
cases (37.7%) with Chinese T-ALL [10]. Similar inci-
dence (22%) of Notch 1 mutations was reported by a
research group from Turkey [8]. However, further
research is needed to collect and investigate more sam-
ples and find out the representational results.
The higher frequency of Notch1 mutation is found in
HD, TAD and PEST domains [5-10]. In the present
study, we used the 4 pair primers covered all the HD,
TAD and PEST domains to amplify and sequence. Two
mutations were identified in three cases, one was the
mutation on 4778 position (L1593P) which was reported
in previous studies [10,17], while the another mutation
was identified on 4733 position (V1578E) in two differ-
ent cases with T-ALL, to our best knowledge, this is a
novel identified mutation. The effect of the novel muta-
tion is needed to evaluate by further functional analysis.
Both mutations were located at HD N-terminus (HD-N)
domain. The Notch1 HD-N mutation may destabilize
the subunit interaction and do not require the ligand-
binding domain to activate signaling, resulting in consti-
tutive Notch1 activation and subsequent cell transforma-
tion [9,17]. Based on the results, we compared the
expression level of Notch1i nT - A L Lw i t hW TNotch1
or with Mut Notch1 group, definitive result indicated
that the expression level of Notch1w a ss i g n i f i c a n ta s s o -
ciated with Notch1m u t a t i o ni nH D - Nd o m a i n ,s i g n i f i -
cantly higher expression of Notch1 was detected in the
T-ALL with Mut Notch1 group compared with WT
Notch1 T-ALL group. However, overexpression of
Notch1 was a common feature in all T-ALL patients,
whether the mechanism of Notch1o v e r e x p r e s s i o ni n
mutation or WT samples is different, it remains an
open question. Although no mutation was detected in
HD, TAD or PEST domains, high expression level of
Notch1 in two cases with T-ALL in the present study
was thought that might has potential mutation in the
other domains, whole notch1 gene sequence analysis for
these cases is needed to follow up.
In the present study, we were unable to identify muta-
tion of Notch1 in PEST domain which regulates protein
turnover by targeting proteins to the ubiquitin-proteo-
some complex for subsequent degradation [9,15].
Figure 3 The expression levels of Notch1g e n ei nT - A L Lw i t hNotch1 mutation (Mut T-ALL), T-ALL with wild type Notch1 (WT T-ALL)
and healthy individuals (HI) groups.
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tion in PEST domain was reported in Indian T-ALL
patients [9], while lower incidence was described from a
study in Chinese T-ALL patients (5/77, 6.5%) [15], as
well as in Turkish patients (7%) and German patients
(8.2%) [7,18], the difference may due to the racial
diversify.
In summary, Notch1 mutations including a novel
mutation were identified in a small cohort of Chinese
T-ALL cases, and concomitant significantly higher
expression level of Notch1w a sf o u n d .M o r eo n g o i n g
study was performed to follow up its predictive value
and to elucidate its contribution to the molecular patho-
genesis of T-ALL.
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